Prazosin for Smoking Cessation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

1 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-07-31

Study Completion Date

2013-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The most likely outcome of smoking cessation attempts is relapse, underscoring the need to advance novel treatments. Preclinical research shows that the noradrenergic system is critical for modulating drug-seeking behavior and recent findings indicate that the α1-adrenergic antagonist prazosin reduces nicotine self-administration and reinstatement. Presently, data on prazosin's effects on nicotine-related behaviour in humans is lacking. An efficient method for screening novel smoking cessation medications is to integrate human laboratory paradigms in the context of brief, randomized trials of smoking cessation that include smokers motivated to quit. This study aims to provide an initial test of prazosin for smoking cessation by implementing a brief, randomized trial that will include both human laboratory and clinical phenotypes. This approach will allow an efficient but sensitive method for medication screening that maximizes clinical validity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigation of Cycloserine as a Smoking Cessation Treatment

NCT01062932

Nicotine Addiction

COMPLETED PHASE1

Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?

NCT01730846

Smoking

COMPLETED PHASE2

A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation

NCT02044874

Smoking Cessation

COMPLETED PHASE2

Varenicline + Prazosin for Heavy Drinking Smokers

NCT02193256

Cigarette Smoking Alcohol Use Disorders

COMPLETED EARLY_PHASE1

Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine

NCT01944423

Nicotine Addiction Panic Attack

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nicotine Dependence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sugar pills

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo capsules, 3x daily

Prazosin pills

Group Type ACTIVE_COMPARATOR

Prazosin

Intervention Type DRUG

Prazosin medication, 3x daily dosing, up to 15mg/day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

Placebo capsules, 3x daily

Intervention Type DRUG

Prazosin

Prazosin medication, 3x daily dosing, up to 15mg/day

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Greater than or equal to 10 cigarettes per day for past year
* Baseline Fagerstrom Test for Nicotine Dependence (FTND) score of greater than or equal to four
* Willing to engage in two practice quit attempts
* Willingness to forgo other medication based treatments during the trial

Exclusion Criteria

* Current illicit drug use
* Current treatment with psychiatric medications other than selective serotonin re-uptake inhibitors (SSRIs)
* Lifetime diagnosis of post-traumatic stress disorder (PTSD)
* Significant medical/neurological illness
* Baseline BP outside of normal range
* Current use of tobacco aids
* Current use of medications that could interact with prazosin
* Pregnancy or nursing

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes